Table 4

Cox proportional hazard models of factors predictive of blast transformation in patients with PMF

Cox model
P
HR (95% CI)
Univariable analysis   
    Age > 50 y 4.92 (2.5-9.7) < .001 
    Female sex 1.49 (0.79-2.8) .21 
    WBC count 1.1 (0.96-1.07) .48 
    Hemoglobin 0.86 (0.79-0.93) < .001 
    PB blasts > 1% 1.12 (0.95-1.33) .17 
    Serum cholesterol level 0.97 (0.96-0.99) .002 
    IPSS score 2.69 (2.09-3.47) < .001 
    CD34+ cell in PB 1..02 (1.01-1.02) < .001 
    JAK2V617F homozygous genotype 3.15 (1.58-6.26) .001 
    G/G genotype of the GR A3669G variant in JAK2 V617F–mutated patients 4.75 (2.06-10.9) < .001 
Multivariable analysis (in JAK2 V617F–mutated patients)   
    Age > 50 y 4.16 (1.58-6.26) < .001 
    JAK2V617F homozygous genotype 2.28 (1.12-4.61) .021 
    G/G genotype of the GR A3669G variant 3.33 (1.40-7.89) .006 
Cox model
P
HR (95% CI)
Univariable analysis   
    Age > 50 y 4.92 (2.5-9.7) < .001 
    Female sex 1.49 (0.79-2.8) .21 
    WBC count 1.1 (0.96-1.07) .48 
    Hemoglobin 0.86 (0.79-0.93) < .001 
    PB blasts > 1% 1.12 (0.95-1.33) .17 
    Serum cholesterol level 0.97 (0.96-0.99) .002 
    IPSS score 2.69 (2.09-3.47) < .001 
    CD34+ cell in PB 1..02 (1.01-1.02) < .001 
    JAK2V617F homozygous genotype 3.15 (1.58-6.26) .001 
    G/G genotype of the GR A3669G variant in JAK2 V617F–mutated patients 4.75 (2.06-10.9) < .001 
Multivariable analysis (in JAK2 V617F–mutated patients)   
    Age > 50 y 4.16 (1.58-6.26) < .001 
    JAK2V617F homozygous genotype 2.28 (1.12-4.61) .021 
    G/G genotype of the GR A3669G variant 3.33 (1.40-7.89) .006 

or Create an Account

Close Modal
Close Modal